Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 08/10/2010) - In this trial, patients with metastatic alveolar soft part sarcoma will be treated with cediranib by mouth once a day in 28-day cycles until disease progression or unacceptable toxicity.
Electroacupuncture for Radiation-Induced Chronic Dry Mouth
(Posted: 07/27/2010) - In this clinical trial, head and neck cancer patients with chronic dry mouth who completed radiation therapy at least 6 months before joining the trial and who received no benefit from treatment with the drug pilocarpine (Salagen) will be randomly assigned to undergo electroacupuncture using a machine called a LISS stimulator, or a sham procedure, using a similar-looking machine that does not produce electrical stimulation.
Inhibiting Angiogenesis in Metastatic Castration-Resistant Prostate Cancer
(Posted: 06/29/2010) - In this trial, patients with metastatic castration-resistant prostate cancer who have received no treatment for metastatic disease will be treated with docetaxel, prednisone, bevacizumab, and lenalidomide.
Targeting the Hedgehog Pathway in Stomach Cancer
(Posted: 06/01/2010) - This phase II will recruit patients with inoperable cancer of the stomach or gastroesophageal junction who have not been previously treated for advanced disease. They will be randomly assigned to receive either the combination chemotherapy regimen FOLFOX plus the Hedgehog antagonist GDC-0449 or FOLFOX plus a placebo.
Vaccine Therapy for Patients with Recurrent Blood Cancers
(Posted: 05/04/2010) - In this phase I/II trial, patients with blood cancer that has recurred after allogeneic stem cell transplantation will be treated with donor T-lymphocyte infusions and a dendritic cell vaccine that is designed to trigger an immune response against cells producing a protein called Wilms tumor 1 (WT1).